Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Sgroi

Showing results (81-90 of 113) with videos related to

Pageof 12
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|December 6, 2011
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncologyPhillip G Febbo, Marc Ladanyi, Kenneth D Aldape, et al.
Breast Cancer Research and Treatment|April 27, 2016
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14Judith-Anne W Chapman, Dennis C Sgroi, Paul E Goss, et al.
Breast Cancer Research : BCR|March 15, 2014
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivityRyan P McMullin, Ben S Wittner, Chuanwei Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapyEmanuel F Petricoin, Verena E Bichsel, Valerie S Calvert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom StudyJohn M S Bartlett, Dennis C Sgroi, Kai Treuner, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2011
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathwayKideok Jin, Xiangjun Kong, Tariq Shah, et al.
Nature Genetics|October 30, 2012
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genesMatthieu Le Gallo, Andrea J O'Hara, Meghan L Rudd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFREzra E W Cohen, Mark W Lingen, Leslie E Martin, et al.
BMC Cancer|November 28, 2014
Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1Meghan L Rudd, Hassan Mohamed, Jessica C Price, et al.
Cancer Research|April 6, 2006
Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesisGromoslaw A Smolen, Beth Muir, Gayatry Mohapatra, et al.
Pageof 12

Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Journal of the National Comprehensive Cancer Network : JNCCN|December 6, 2011
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncologyPhillip G Febbo, Marc Ladanyi, Kenneth D Aldape, et al.
Breast Cancer Research and Treatment|April 27, 2016
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14Judith-Anne W Chapman, Dennis C Sgroi, Paul E Goss, et al.
Breast Cancer Research : BCR|March 15, 2014
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivityRyan P McMullin, Ben S Wittner, Chuanwei Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapyEmanuel F Petricoin, Verena E Bichsel, Valerie S Calvert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom StudyJohn M S Bartlett, Dennis C Sgroi, Kai Treuner, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2011
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathwayKideok Jin, Xiangjun Kong, Tariq Shah, et al.
Nature Genetics|October 30, 2012
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genesMatthieu Le Gallo, Andrea J O'Hara, Meghan L Rudd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFREzra E W Cohen, Mark W Lingen, Leslie E Martin, et al.
BMC Cancer|November 28, 2014
Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1Meghan L Rudd, Hassan Mohamed, Jessica C Price, et al.
Cancer Research|April 6, 2006
Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesisGromoslaw A Smolen, Beth Muir, Gayatry Mohapatra, et al.
Pageof 12